In terms of “druggability” of the BLS in AD, it is plausible that VEGFR 3 (Vascular endothelial growth factor receptor 3), a member of VEGFRs family involved in developing and establishing new lymphatic system structures (Secker and Harvey, 2021) may become a pharmacological target against AD. Here, FLT4 is linked to Alzheimer disease.